TARGT IndiegeneTM Liquid is a minimally invasive and comprehensive cancer gene panel that provides information on the biology of the tumor in terms of its current status and its response to therapy from peripheral blood. 
This panel has been indigenously developed and validated at 4baseCare laboratories, constituting a comprehensive core list of cancer-related genes (1212 genes) derived from high throughput next-generation sequencing of 1500+ cancer patients on whole-exome across 28 different cancer types.
The scope of the assay includes circulating tumor DNA (ctDNA) based genomic profiling for cancer patients to detect genomic alterations such as SNVs/InDels, CNAs, Gene Fusions/Splice Variant, and MSI.
The detection of Gene Fusion is limited to therapeutically relevant fusions that are more frequent in NSCLCs (ALK, ROS1, RET, NTRK, FGFR 2, and FGFR3).
Consult our Genetic Counselor to find the right test for you.
Kindly fill the form below to download our